These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 12647443

  • 21. [Social cognition and atypical antipsychotic agents in the treatment of persons with schizophrenia: preliminary data from a naturalistic study].
    Mazza M, Tozzini C, Giosué P, De Risio A, Palmucci M, Roncone R, Casacchia M.
    Clin Ter; 2003; 154(2):79-83. PubMed ID: 12856365
    [Abstract] [Full Text] [Related]

  • 22. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A, Ritsner MS.
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [Abstract] [Full Text] [Related]

  • 23. Long-term administration of the low-dose risperidone in schizotaxia subjects.
    Rybakowski JK, Drozdz W, Borkowska A.
    Hum Psychopharmacol; 2007 Aug; 22(6):407-12. PubMed ID: 17597479
    [Abstract] [Full Text] [Related]

  • 24. [Frontal dementia or dementia praecox? A case report of a psychotic disorder with a severe decline].
    Vanderzeypen F, Bier JC, Genevrois C, Mendlewicz J, Lotstra F.
    Encephale; 2003 Aug; 29(2):172-80. PubMed ID: 14567169
    [Abstract] [Full Text] [Related]

  • 25. Remission in schizophrenia: analysis in a naturalistic setting.
    Eberhard J, Levander S, Lindström E.
    Compr Psychiatry; 2009 Aug; 50(3):200-8. PubMed ID: 19374962
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
    Ruhrmann S, Kissling W, Lesch OM, Schmauss M, Seemann U, Philipp M.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun 30; 31(5):1012-22. PubMed ID: 17412473
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
    Himei A, Okamura T.
    Psychiatry Clin Neurosci; 2005 Oct 30; 59(5):556-62. PubMed ID: 16194258
    [Abstract] [Full Text] [Related]

  • 28. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
    Perez V, Cañas F, Tafalla M, TESIS Study Group.
    Int Clin Psychopharmacol; 2008 May 30; 23(3):138-49. PubMed ID: 18408528
    [Abstract] [Full Text] [Related]

  • 29. [A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone].
    Sannomiya M, Katsu H, Nakayama K.
    Seishin Shinkeigaku Zasshi; 2003 May 30; 105(5):643-58. PubMed ID: 12875232
    [Abstract] [Full Text] [Related]

  • 30. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM, Yu SC, Lin CC.
    J Clin Psychiatry; 2003 Nov 30; 64(11):1342-8. PubMed ID: 14658949
    [Abstract] [Full Text] [Related]

  • 31. Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients.
    Lee SM, Chou YH, Li MH, Wan FJ, Yen MH.
    J Psychiatr Res; 2008 Mar 30; 42(4):328-35. PubMed ID: 17412363
    [Abstract] [Full Text] [Related]

  • 32. Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission.
    Morozova MA, Beniashvili AG, Lepilkina TA, Rupchev GE.
    Psychiatr Danub; 2012 Jun 30; 24(2):159-66. PubMed ID: 22706414
    [Abstract] [Full Text] [Related]

  • 33. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC, Lung FW, Chong MY.
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar 30; 28(2):285-90. PubMed ID: 14751424
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M, Kuwilsky A, Krumm B, Dressing H.
    J Psychopharmacol; 2009 May 30; 23(3):305-14. PubMed ID: 18562423
    [Abstract] [Full Text] [Related]

  • 35. [Intensity of negative symptoms, working memory and executive functions disturbances in schizophrenic patients in partial remission period].
    Hintze B, Borkowska A.
    Psychiatr Pol; 2011 May 30; 45(4):457-67. PubMed ID: 22232973
    [Abstract] [Full Text] [Related]

  • 36. The effects of clozapine and risperidone on spatial working memory in schizophrenia.
    McGurk SR, Carter C, Goldman R, Green MF, Marder SR, Xie H, Schooler NR, Kane JM.
    Am J Psychiatry; 2005 May 30; 162(5):1013-6. PubMed ID: 15863811
    [Abstract] [Full Text] [Related]

  • 37. Effect of risperidone on emotion recognition deficits in antipsychotic-naïve schizophrenia: a short-term follow-up study.
    Behere RV, Venkatasubramanian G, Arasappa R, Reddy N, Gangadhar BN.
    Schizophr Res; 2009 Aug 30; 113(1):72-6. PubMed ID: 19545977
    [Abstract] [Full Text] [Related]

  • 38. Marked improvement of tardive dystonia after replacing haloperidol with risperidone in a schizophrenic patient.
    Yoshida K, Higuchi H, Hishikawa Y.
    Clin Neuropharmacol; 1998 Aug 30; 21(1):68-9. PubMed ID: 9579290
    [Abstract] [Full Text] [Related]

  • 39. [Neuropsychological deficits, obstetric complications and premorbid adjustment in patients with the first psychotic episode].
    Casar C, Artamendi M, Gutiérrez M, Gil P, García MJ, Cuesta MJ.
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997 Aug 30; 25(5):303-7. PubMed ID: 9547214
    [Abstract] [Full Text] [Related]

  • 40. [Working memory in schizophrenia: a review].
    Kebir O, Tabbane K.
    Encephale; 2008 Jun 30; 34(3):289-98. PubMed ID: 18558152
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.